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Introduction 
 
The very essence of diabetes is the failure of the insulin-producing 
pancreatic beta cells, either due to autoimmune destruction in type 1 
diabetes or as a consequence of permanent glucotoxicity combined 
with peripheral insulin resistance in type 2 diabetes. Diabetes 
mellitus in all its forms is a serious and costly disease and it has 
become a major health problem worldwide during the past few 
decades. Patients with diabetes require a life-long therapy, and 
complications can decrease quality of life substantially. Both type 1 
and type 2 diabetes is complicated by severe end-organ damage in 
vital organs of the body including the retina, the kidney glomerulus 
and peripheral nerves, because of the long-term effects of chronic 
hyperglycaemia on the microvasculature. People with diabetes are 
also at greater risk for developing artherosclerosis, affecting 
coronary, cerebrovascular and peripheral arterial circulation. Data 
strongly imply that normalization of blood glucose levels is essential 
early in the time course of diabetes in order to prevent or delay 
micro- and macrovascular complications. There has been an 
impressive improvement in the treatment of diabetes with higher 
standards of care, advances in insulin therapy and new medications; 
however, the quest for cure still remains. Consequently, much 
research effort has been made to understand beta cell development, 
beta cell biology with detailed mechanisms of insulin secretion and 
the pathophysiological changes that occur to beta cells in diabetes.  
 
Characterizing the embryogenic processes of pancreas and islet 
development and understanding the transcription factor cascade that 
drive beta cell specialization may hold the key for cell-based 
therapies for diabetes. Since 1970’s beta cell replacement has been 
attempted with whole pancreas transplantation, or isolated islet 
transplantation. However, the need for life-long immunosuppression, 
the limited availability of donor tissue, the potential surgical 
complications and graft function failure rendered these therapies 
suboptimal and not widely used. Therefore, research efforts have 
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turned to alternative means of generating beta-cells. Theoretically, 
beta cells could be derived in vitro from stem or precursor cells 
thorough gene transfer of transcription factors, under experimental 
conditions. In the future, these in vitro generated beta cells could 
potentially be transplanted into patients.  
 
Beta cell differentiation process has been studied extensively in mice, 
and today we know that there are four distinct phases of beta cell 
generation. The first phase is the primary endocrine cell phase 
(before embryonic day 13 in mice) during which a few endocrine 
cells are generated in the dorsal and ventral pancreatic bud, which are 
mostly glucagon positive, with few insulin positive cells. These cells 
contain low levels of insulin, co-express glucagon, and lack mature 
beta cell markers. The next phase is called secondary transition 
(embryonic days 13-18 in mice), during which beta cell neogenesis 
from ductal epithelium (tubular progentiors) accelerates dramatically, 
and the newly formed cells are more similar to mature beta cells. The 
process of differentiation of progenitor cells down the endocrine 
linage is initiated by the transient expression of transcription factor 
Ngn3, and beta cells are also characterized by expressing Pdx1 
(pancreatic and duodenal homeobox 1) and NeuroD1 (neurogenic 
differentiation 1). Simultaneously, exocrine acinar cells start to 
differentiate. The third phase of beta cell formation starts shortly 
before birth and lasts through the first few weeks of postnatal life and 
is characterized by a significant expansion in beta cells due to 
proliferation. Similar beta cell expansion is also described in human 
neonates. Beta cell maturation also occurs in this period, leading to a 
mature beta cell phenotype with regulated, glucose-stimulated insulin 
secretory response. Transcription factor MafA (musculoaponeurotic 
fibrosarcoma oncogene homolog A) appears in beta cells from this 
period. The final phase of beta cell generation occurs in adulthood, 
when replacement or expansion of beta cell mass happens in 
response to metabolic needs. This period is not well characterized, 
and latest research suggests that in mice, adult beta cell regeneration 
mostly depends on proliferation of preexisting beta cells rather than 
  4 
neogenesis; whereas in humans, neogenesis from pancreatic ductal 
epithelium and beta cell proliferation probably contributes equally to 
the regeneration process. 
 
Transcription factors seem to have a dual role in beta cell function: 
determining early cellular development, and later maintaining the 
phenotype of terminally differentiated cells. Regulated expression of 
transcription factors is critical, because disruption of these genes has 
resulted in phenotypes of impaired development of the pancreas and 
consequent diabetes. Furthermore, lessons learned from the gene 
knock-outs in mice have been used to successfully identify mutations 
in several of the corresponding orthologous genes in individuals with 
familial monogenic type 2 diabetes (MODY). In pathological 
conditions such as in chronic glucotoxity, beta cell dysfunction 
develops with impaired glucose-stimulated insulin secretion, down-
regulation of several important genes of the beta cell metabolism and 
also lower levels of MafA. Taken together, detailed characterization 
of beta cell specific transcription factors are highly important to 
understand the molecular mechanisms of diabetes, and it seems 
realistic that these molecules may become targets of drug 
development in the near future. 
 
Adult, functional beta cells are characterized by rapid and precise 
changes in insulin secretion in response to nutrient secretagogues, 
particularly glucose, that maintain blood glucose levels in the 
physiologically relevant range. Specialised metabolic pathways 
ensure the coupling of external nutrient stimuli to insulin secretion in 
adult beta cells (Figure 1), and insulin gene transcription is regulated 
by Pdx1, NeuroD1 and MafA together. Glucose entering the beta cell 
is quickly metabolized to pyruvate and the glucose-derived carbons 
are then oxidized in the mitochondria. The very low expression of 
lactate dehydrogenase and monocarboxylate transporters results in 
negligible lactate production. Simultaneously, glycolysis-derived 
cytosolic NADH is reoxidized in mitochondrial membrane shuttles, 
and the strong pyruvate carboxylase activity of beta cells further 
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facilitates the flux of pyruvate to the shuttles. Glucose oxidation 
promotes the production of ATP, the key metabolic coupling factor 
for glucose-stimulated insulin secretion (GSIS). The closing of ATP-
dependent K
+ 
channels results in depolarisation, opening of voltage-
activated Ca
2+
 channels and subsequent exocytosis of the preformed 
insulin granules. The fine tuning of GSIS is ensured by the distinct 
expression pattern of metabolic pathways in beta cells compared to 
other cell types. 
 
Figure 1. The current concept of glucose-stimulated insulin secretion in 
pancreatic beta cells, described in details in the text. Abbreviations: glc, glucose; 
OxPhos, oxidative phosphorylation; ΔΨ, membrane depolarisation. 
 
Although the metabolism of adult beta cells has been characterised 
extensively, that of immature fetal/neonatal beta cells, which are 
glucose unresponsive, is less well understood. Similarly, molecular 
mechanisms in diabetic, dysfunctional beta cells are poorly 
characterized.  Neonatal, immature and diabetic, dysfunctional beta 
cells may seem quite different, but they share a common phenotype: 
lack normal GSIS.  
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My research work was focused on the metabolic gene and 
transcritption factor expression patterns that drive the change of beta 
cell phenotype. 
 
 
Aims 
 
The general objective of my PhD thesis is to provide a molecular 
description of the evolving beta cell phenotype; from the immature 
neonatal period, through the mature, glucose-responsive stage, to the 
development of glucotoxicity and a dysfunctional beta cell 
phenotype. 
 
AIM 1. To characterize the underlying mechanisms responsible 
for the immature, glucose-unresponsive phenotype of neonatal 
beta cells. 
Postulating that the mechanisms responsible for neonatal beta cell 
immaturity are  complex, we used microarray analysis to compare the 
gene expression profile of neonatal (postnatal day P1) and adult beta 
cells excised by laser-capture microdissection. Sets of genes with 
differential expression were confirmed with quantitative realtime 
PCR (qPCR) and immunostaining. Moreover, expression pattern of 
these genes were followed during the first weeks of postnatal life, as 
the insulin secretion of the islets matures. 
 
AIM 2. To assess whether maturation of neonatal beta cells into 
glucose-responsive, mature insulin secreting cells is regulated by 
transcription factor MafA and/or Pdx1. 
We characterized the expression of MafA and Pdx1 and that of other 
key beta cell genes during the first 4 weeks of postnatal life. We 
hypothesized that enhancing the expression levels of these factors in 
neonatal beta cells could drive the acquisition of glucose-responsive 
insulin secretion.  
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AIM 3. To characterize the importance of MafA in regulating 
beta cell function in adult rat islets.  
We hypothesized that there is a causal relationship between MafA 
expression and functional integrity of adult beta cell; and we aimed at 
studying MafA targets besides insulin with the inhibition of MafA 
function in adult rat beta cells.  
 
AIM 4. To test the role of MafA in dysfunctional beta cells. 
It is known that MafA expression level is lower and GSIS is impaired 
in beta cells under glucotoxicity. We investigate the ability of MafA 
overexpression in a diabetic model to restore glucose-stimulated 
insulin secretion. 
 
 
Methods 
 
1. Animal studies 
Adult male and female Sprague-Dawley rats were used for animal 
studies, and 1-day-old pups were used for neonatal beta-cell 
experiments. As a diabetic model, Goto-Kakizaki (GK) rats were 
investigated with age-, gender-matched Wistar-Kyoto rats as 
controls. Animals were purchased from Taconic Farms 
(Germantown, NY). All procedures were approved by the Joslin 
Institutional Animal Care and Use Committee. Rats were 
anaesthetized with Nembutal. For immunostaining, excised 
pancreases were fixed by immersion in 4% paraformaldehyde, and 
were then embedded in paraffin. For laser capture microdissection 
(LCM), pancreases were immersed in TissueTek OCT medium and 
then were rapidly frozen. Islet isolation were done by collagenase 
digestion and gradient separation according to the protocol published 
by Gotoh et al. in 1987. 
 
2. Laser-capture microdissection  
Beta cell-enriched cores of islets were microdissected using a PixCell 
II LCM system (Arcturus, Mountain View, CA) from frozen 
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pancreatic sections. For each sample, two to five islets per section 
were excised from 10–20 sections, then total RNA from was 
extracted and amplified for the microarray. 
 
 
3. Microarray hybridization  
Biotinylated cDNA of four adult and four neonatal beta cell-enriched 
samples were made of total RNA and were subsequently run on 
Affymetrix GeneChip Rat Genome U34A (Affymetrix, Santa Clara, 
CA). Analysis was performed using a DNA-Chip Analyzer (dChip; 
Harvard School of Public Health, Boston). Lower confidence 
boundary (LCB) and p values (<0.050) were used to assess 
differentially expressed genes between neonate and adult rats. Genes 
were then classified into functionally related clusters using DAVID 
software. 
 
4. Adenovirus infection 
Recombinant adenoviruses were generated to direct expression of 
transcription factors in beta-cells using the AdEasy system 
(Stratagene, La Jolla, CA). The following adenoviruses were used: 
AdMafA, expressing the full human MafA coding sequence; AdDN-
MafA, containing a dominant negative mutant of MafA lacking the 
N-terminal transcriptional activation domain; AdNeuroD1, 
expressing the hamster NeuroD1 coding sequence; and an adenovirus 
encoding green fluorescent protein alone (AdGFP) served as control. 
AdPdx1 was a kind gift from Dr. D. Melton. All adenoviruses were 
amplified in 293Ad cells and purified with the Vivapure 
AdenoPACK 100 kit (Sartorius, Gottingen, Germany). Virus titers 
were established based on quantification of plaque formation. For 
beta-cell infections, islets were dispersed to single cells using trypsin 
to ensure uniform adenoviral infections during an overnight 
incubation, and were then reaggregated. 
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5. RNA extraction and reverse transcription  
Total RNA from isolated islets or dispersed and reaggregated islet 
cells was extracted using RNeasy Plus Mini Kit (Qiagen, 
Germantown, MD). Next, cDNA was produced using Superscript II 
reverse transcriptase (Invitrogen, Carlsbad, CA).  
 
6. Quantitative real-time PCR (qPCR)  
The qPCR with SYBR Green detection was performed using the 
ABI7300 Real-time PCR System (Applied Biosystems, Foster City, 
CA) with primers designed using Primer Express. The comparative 
CT (threshold cycle) method was used to calculate relative gene 
expression levels, after normalization of the gene of interest to a 
control ribosomal gene (L32 or S25).  
 
7. Insulin secretion in vitro 
Insulin secretion of the islet cell aggregates was measured in the 
supernatant with sequential static incubations at low (2.8mM) and 
high (16.7mM) glucose Krebs-Ringer bicarbonate buffer. The Insulin 
Rat EIA kit (ALPCO Diagnostics, Salem, NH) was used for analysis. 
 
8. Insulin secretion in vivo: intra-peritoneal glucose tolerance test  
For intraperitoneal glucose tolerance tests (IPGTT), rats were fasted 
with free access to water only, for 8–12 h. Rats were then injected 
intraperitoneally with 10% glucose solution at a dose of 2 g/kg body 
weight. Blood glucose readings were performed from the tail vein 
every half hour for two hours in total with OneTouch Ultra blood 
glucose meter (LifeScan, Milpitas, CA). 
 
9. Western Blot 
Protein quantities were established by Western Blot analysis. After 
AdMafA and AdDN-MafA infections, islet cell aggregates were 
sonicated, and then boiled in the presence of β-mercaptoethanol. 
Next, protein extract was resolved on SDS-PAGE electrophoresis, 
transferred to PVFD membranes and probed with either MafA 
antibody (developed by Nishimura et al.) or HSV antibody (Abcam, 
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Cambridge, MA), which detects the HSV-tagged DN-MafA protein. 
Secondary antibodies were conjugated to horseradish peroxidase,  
and blots were visualized based on chemiluminescence (SuperSignal 
West Dura reagent, Pierce, Thermo Fisher Scientific, Waltham, MA). 
 
 
10. Immunohistochemistry 
Paraffin embedded pancreatic sections were stained for pyruvate-
kinase and glycerol-3P-dehydrogenase following general 
immunostaining protocols, antibodies were developed by US 
Biological, Swampscott, MA and Dr. M. MacDonald. As a second 
step, biotin-streptavidin amplification was used. Finally protein 
quantities were detected based on peroxidase reaction for pyruvate-
kinase and immunofluorescence for glycerol-3P-dehydrogenase. In 
another set of experiments, GK and WKY rat pancreases were 
studied for beta cell composition, and sections were double stained 
with anti-insulin and a cocktail of anti-non-beta cell hormones. 
Histological sections were imaged by Olympus BH2 and Zeiss 710 
LSM microscopes.  
 
11. Statistical analysis 
For statistical analysis, unpaired Student’s t test was used. To see 
differences among groups, ANOVA was used followed by post hoc 
analysis (Tukey’s). A p value <0.050 was considered statistically 
significant. 
 
 
Results 
 
Neonatal and mature beta-cells have distinct gene expression 
patterns, several metabolic enzymes important for insulin 
secretion are expressed lower in the neonatal period. 
In the first phase of my research, I studied the gene expression profile 
of immature, neonatal beta cells. Previous studies have described 
single genes being expressed lower in neonatal cells; however, 
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according to our hypothesis, generalized low expression of key 
metabolic enzymes may account for the poor glucose-responsiveness 
of neonatal beta cells. Gene expression profile of neonatal, immature 
beta cells, excised by laser capture microdissection from rat 
pancreatic islets was compared to adult, mature cells. Several 
mRNA-s of beta cell important enzymes were found to be lower in 
the neonatal period (pyruvate-carboxylase, GLP1-receptor, enzymes 
of the reducing equivalent transport through mitochondrial 
membrane, such as malate-dehydrogenase, glycerol-3-phosphate-
dehydrogenase, malic enzyme), which could explain the insufficient 
glucose-stimutaled insulin secretion at this age. Microarray results 
were confirmed by real-time PCR, and by immunohistochemical 
staining of selected metabolic enzyme proteins (pyruvate-kinase, 
glycerol-3-phosphate-dehydrogenase). While studying the 
development of the characteristic metabolic profile of adult beta 
cells, we confirmed that the expression level of these genes gradually 
increase over the first postnatal month, in parallel with the 
appearance of the glucose-stimulated insulin secretion.  
 
Expression level of transcription factors change over the 
postnatal period. MafA plays an important role in the induction 
of glucose-stimulated insulin secretion. 
The reduced expression of many key beta cell genes in neonatal beta 
cells suggests that regulated expression of transcription factors may 
drive beta cell maturation. Key beta cell specific, glucose-regulated 
transcription factors Pdx1, NeuroD1 and MafA were studied, and 
compared with the expression profile of metabolic enyzmes and 
insulin during the first postnatal month in rats. All these transcription 
factors are glucose regulated; Pdx1 plays a role in early endocrine 
differentiation, NeuroD1 is a late differentiation factor, and whereas 
MafA is a beta cell maturation factor that aso regulates insulin 
synthesis and secretion, according to our hypothesis. Of these studied 
transcription factors, expressional profile of MafA gradually 
increased over the first postnatal months, similarly to metabolic 
enzymes. Protein levels of MafA were quantitated by Wester blot 
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analysis, and found to be extremely low in day 1, markedly increased 
by day 10, but still lower than in adults. In the second phase of my 
studies, expression level of MafA was exogenously enhanced in 
neonatal rat islet cells by adenoviral infection and overexpression the 
MafA protein, which resulted in induction of important metabolic 
enzymes. Importantly, by enchancing the expression level of MafA, 
glucose-stimulated insulin secretion also significantly increased 
when compared to control neonatal cells. In contrast, overexpression 
of Pdx1 did not influence the insulin release. Taken together, we 
established that beta cell maturation could be accelerated with 
overexpression of MafA. 
 
Transcription factor MafA as a regulator molecule in adult, 
mature beta-cells. 
Next, I aimed to characterize the importance of MafA in regulating 
beta cell function in adult rat islets, and tested the effect of MafA 
inhibition in adult, mature beta cells. MafA function was selectively 
inhibited by a “dominant-negative” MafA construct (DN-MafA), 
which codes a mutant DN-MafA protein, lacking the N-terminal 
transcriptional activation domain. The DN-MafA construct was 
transfected into freshly isolated rat islet cells by adenovirus mediated 
infection. The expressed DN-MafA protein would bind to the 
endogenous MafA and inhibit its transcriptional activity. Endogenous 
MafA mRNA and protein levels decreased to 10% as compared to 
control untreated beta cells, suggesting MafA autoregulation. Low 
levels of MafA resulted in decreased expression of several metabolic 
enzymes, beta cell specific genes and other transcription factors. 
Gene expressional changes were followed for 72 hours after DN-
MafA infections, and mRNA levels of glucokinase, GLUT1, insulin, 
PCSK enzyme, GLP1-receptor, Kir6.2 potassium channel, and 
multiple enzymes of the reducing equivalent transport significantly 
reduced. In contrast, mRNA level of lactate-dehydrogenase, which is 
virtually not expressed in adult beta cells, increased significantly. 
Functional studies revealed that glucose-stimulated insulin secretion 
becomes impaired at 36 hours after DN-MafA infection, which 
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coincides with the time when expression of beta cell important 
metabolic genes decrease. The results suggest that beta cells become 
dysfunctional, dedifferentiated with the loss of functional MafA, and 
they acquire a phenotype similar to neonatal, immature beta cells. 
 
MafA overexpression in dysfunctional, diabetic beta-cells can 
increase glucose-stimulated insulin secretion. 
Previous studies have shown that chronic hyperglycaemia, typical of 
diabetes, induces similar phenotypic changes as described above, as 
beta cells become dedifferentiated. It is also known that glucose-
stimulated insulin secretion of diabetic beta cells is impaired. 
According to a recent animal study, hyperglycaemia causes a 
decrease in MafA expression. Based on these results, in the last phase 
of my studies I aimed to restore MafA function in impaired beta cells 
of diabetic rats by overexpressing MafA, and sought to improve 
glucose-stimulated insulin secretion. I studied Goto-Kakizaki rats, 
the prototype animal model of spontaneous type 2 diabetes. As 
expected, adenovirus mediated overexpression of MafA increased 
glucose-stimulated insulin secretory response in 48-72 hours.    
 
Figure 2: Paradigm of the beta cell, with MafA as a critical regulator of beta cell 
phenotype. 
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Conclusions 
 
Low levels of transcription factor MafA causes low expression of 
several beta-cell important genes and blunted glucose-stimulated 
insulin secretion, a phenotype typical of neonatal, immature beta-
cells as well as diabetic, dedifferentiated beta-cells  (Figure 2). 
Restoring MafA function can the increase insulin secretory response. 
Transcription factor MafA regulates the expression of several beta 
cell important genes directly or indirectly, besides regulating insulin 
gene expression as well. Thus, the presence of MafA is indispensable 
for mature beta cell function and physiologic glucose-stimulated 
insulin secretion. 
 
Based on our results, transcription factor MafA may serve as a 
potential candidate for drug development for treating patients with 
type 2 diabetes, since it could prevent beta cell dedifferentiation and 
may enhance insulin secretion. 
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